Results 141 to 150 of about 2,272 (175)
Some of the next articles are maybe not open access.
Evaluation of Eravacycline: A Novel Fluorocycline
Pharmacotherapy, 2020Eravacycline (ERV), formerly known as TP‐434, is a novel tetracycline (TET) antibiotic that exhibits in vitro activity against various gram‐positive, gram‐negative aerobic and anaerobic pathogens, including those exhibiting TET‐specific acquired resistance mechanisms.
Sara Alosaimy +1 more
exaly +3 more sources
Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits
Antimicrobial Agents and Chemotherapy, 2018 Eravacycline (7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline or TP-434) is a novel, fully synthetic broad-spectrum fluorocycline with potent activity against Gram-positive bacteria, anaerobes, and multidrug-resistant
Ieva Alisauskaite +12 more
exaly +2 more sources
Prolonged course of eravacycline leading to acute pancreatitis
American Journal of the Medical Sciences, 2023Eravacycline is the newest member of the broad-spectrum class of tetracycline antimicrobials. Pancreatitis has been previously associated with the tetracycline class of antibiotics, but, to our knowledge, we believe that this is the first reported case of eravacycline-induced pancreatitis.
Michael S Gelfand, B Tate Cutshall
exaly +3 more sources
Eravacycline: The Tetracyclines Strike Back
Annals of Pharmacotherapy, 2019Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of eravacycline, a novel fluorocycline antibiotic from the tetracycline family. Data Sources: A PubMed search was conducted for data between 1946 and March 2019 using MeSH terms eravacycline and TP-434.
Maria Heaney +2 more
openaire +2 more sources
Impact of eravacycline on fibrinogen
Journal of Antimicrobial ChemotherapyAbstract Objectives While tigecycline has been associated with hypofibrinogenaemia, limited data with eravacycline suggest this may also occur with this agent. However, the incidence and clinical significance of this finding are not well defined.
Emily Stevenson +6 more
openaire +2 more sources
Eravacycline for the treatment of patients with bacterial infections
Drugs of Today, 2018Eravacycline is a novel, broad-spectrum, synthetic fluorocycline antibiotic for the treatment of complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI) due to multidrug-resistant Gram-positive, Gram-negative and anaerobic bacteria that has demonstrated superior potency to that of currently marketed antibiotics ...
R, Thakare, A, Dasgupta, S, Chopra
openaire +2 more sources
Eravacycline for the treatment of complicated intra-abdominal infections
Expert Review of Anti-infective Therapy, 2019Introduction: Complicated intra-abdominal infections (cIAIs) are among the most frequent infections, contributing to significant morbidity and healthcare costs. Several medical needs remain unmet, related to the pharmacokinetic capacities of the available drugs and their limited spectrum of activity for targeting multidrug-resistant Gram-negative and ...
Philippe, Montravers +2 more
openaire +2 more sources
Detection and characterization of eravacycline heteroresistance in clinical bacterial isolates
Frontiers in MicrobiologyEravacycline (ERV) has emerged as a therapeutic option for the treatment of carbapenem-resistant pathogens. However, the advent of heteroresistance (HR) to ERV poses a challenge to these therapeutic strategies. This study aimed to investigate ERV HR prevalence among common clinical isolates and further characterize ERV HR in carbapenem-resistant ...
Weiguo Yin
exaly +4 more sources